Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-03-01
2011-03-01
Desai, Rita J (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07897620
ABSTRACT:
The invention relates to the use of 3-(2′,2′-dimethylpropanoylamino)-tetrahydropyridin-2-one for preparing a medicament intended to prevent or treat inflammatory disorders.
REFERENCES:
patent: 5593827 (1997-01-01), Bycroft et al.
patent: 5776974 (1998-07-01), Bycroft et al.
patent: 5969158 (1999-10-01), Bycroft et al.
patent: 6395282 (2002-05-01), Kende et al.
patent: 6602905 (2003-08-01), Gardiner et al.
patent: 2002/0025957 (2002-02-01), Stein et al.
patent: 2006/0233728 (2006-10-01), Sagawa et al.
patent: 2009/0036486 (2009-02-01), Grainger et al.
patent: 0519877 (1992-12-01), None
patent: 0443588 (1999-06-01), None
patent: 1374365 (1974-11-01), None
patent: 04-211089 (1992-08-01), None
patent: 10265761 (1998-10-01), None
patent: WO-8910961 (1989-11-01), None
patent: WO-9501175 (1995-01-01), None
patent: WO-9825951 (1998-06-01), None
patent: WO-9912933 (1999-03-01), None
patent: WO-9912968 (1999-03-01), None
patent: WO-9927786 (1999-06-01), None
patent: WO-9931506 (1999-06-01), None
patent: WO-9931507 (1999-06-01), None
patent: WO-0035871 (2000-06-01), None
patent: WO-0126650 (2001-04-01), None
patent: WO-0168655 (2001-09-01), None
patent: WO-02052949 (2002-07-01), None
patent: WO-2004022536 (2004-03-01), None
patent: WO-2005053702 (2005-06-01), None
patent: WO-2005075439 (2005-08-01), None
patent: WO-2006016152 (2006-02-01), None
patent: WO-2006018609 (2006-02-01), None
patent: WO-2006024815 (2006-03-01), None
patent: WO-2006076442 (2006-07-01), None
patent: WO-2006085096 (2006-08-01), None
patent: WO-2006134378 (2006-12-01), None
patent: WO-2006134384 (2006-12-01), None
patent: WO-2006134385 (2006-12-01), None
“U.S. Appl. No. 11/833,022 Notice of Allowance Mailed Sep. 30, 2009”, 6.
“U.S. Appl. No. 11/833,022 Non-Final Office Action Mailed on Sep. 16, 2008”, OARN, 2 Pgs.
“U.S. Appl. No. 11/833,022, Response filed Aug. 31, 2009 to Final Office Action mailed Jul. 10, 2009”, 8 pgs.
“U.S. Appl. No. 11/833,022, Response filed Mar. 13, 2009 to Non-Final Office Action mailed Sep. 16, 2008”, 14 pgs.
“U.S. Appl. No. 11/833,022, Final Office Action mailed Jul. 10, 2009.”, 14 Pgs.
“International Application No. PCT/GB2006/002218 International Preliminary Report on Patentability mailed May 30, 2007”, 9 pgs.
“International Application No. PCT/GB2006/002218 International Search Report and Written Opinion mailed Dec. 14, 2006”, 19 pgs.
“United Kingdom Application No. GB0512238.7 Search Report mailed Sep. 12, 2005”, 3 pgs.
Batrakov, S. G., et al., “A New Ornithine-Containing Lipid From Actinomyces No. 660-15”,Chemistry of Natural Compounds 8(2), (Mar. 1974), 153-158.
Clarke, D. R., et al., “Synthesis and Mass Spectra of Some 3-Acylamino-2-piperidones”,J. Chem. Soc. C: Organic, (1971), 3743-3748.
Cotman, Carl W., et al., “A Potential Role for Apoptosis in Neurodegeneration and Alzheimer's Disease”,Molecular Neurobiology 10(1), (1995), 19-45.
Fox, David J., et al., “Design, Synthesis, and Preliminary Pharmacological Evaluation of N-Acyl-3-aminoglutarimides as Broad-Spectrum Chemokine Inhibitors in Vitro and Anti-inflammatory Agents in Vivo”,J. Med. Chem. 45, (2002), 360-370.
Fox, David J., et al., “Identification of 3-(Acylamino)azepan-2-ones as as Stable Broad-Spectrum Chemokine Inhibitors Resistant to Metabolism in Vivo”,J. Med. Chem 48, (2005), 867-874.
Fringuelli, Renata, et al., “Synthesis and evaluation of anti-apoptotic activity of L-carnitine cyclic analogues and amino acid derivatives”,Il Farmaco 59(4), (Apr. 4, 2004), 271-277.
Frow, Emma K., et al., “Tools for Anti-Inflammatory Drug Design: In Vitro Models of Leukocyte Migration”,Medicinal Research Reviews 24(3), (2004), 267-298.
Gao, Xuri, et al., “Catalytic Asymmetric Synthesis of a Potent Thiomarinol Antibiotic”,J. Am. Chem. Soc. 127(6), (Feb. 16, 2005), 1628-1629.
Gould, Philip L., “Salt selection for basic drugs”,International Journal of Pharmaceutics 33, (1986), 201-217.
Grainger, David J., et al., “Broad spectrum chemokine inhibitors related to NR58-3.14.3”,Mini-Reviews in Medicinal Chemistry 5, (2005), 825-832.
Grainger, David J., et al., “Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo”,Biochemical Pharmacology 65, (2003), 1027-1034.
Jiao, Ying, et al., “Structural Identification of Cepaciamide A, a Novel Fungitoxic Compound fromPseudomonas cepaciaD-202”,Tetrahedron Letters 37(7), (1996), 1039-1042.
Reckless, Jill, et al., “Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines”,Biochem. J. 340, (1999), 803-811.
Reckless, Jill, et al., “The pan-chemokine inhibitor NR58-3.14.3 abolishes tumour necrosis factor-a accumulation and leucocyte recruitment induced by lipopolysaccharide in vivo”,Immunology 103(2), (2001), 244-254.
Schreiber, J., et al., “The Reaction of Cyanogen Bromide with Mono- and Diamino Acids”,Journal of the American Chemical Society 86(12), (Jun. 20, 1964), 2441-2445.
Fox David John
Grainger David J.
Bone Richard G. A.
Cambridge Enterprise Limited
Desai Rita J
Mabry John
Virtual Law Partners LLP
LandOfFree
Methods of using anti-inflammatory compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of using anti-inflammatory compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of using anti-inflammatory compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2703448